Feedback says that its TexRAD medical imaging technology has been shown to assist in early treatment of bowel cancer.
TexRAD and related medical technology company CCI were acquired by Feedback in May. TexRAD is still developing its product so that it can be used commercially in pharmaceutical and it is seeking regulatory approval for this use. Feedback is hopeful that FDA approval can be achieved by next May. TexRAD has already secured Imaging Endpoints as a worldwide partner for lab imaging.
Last month, Nick Shepheard stepped down from the board.
At 1.43p a share, Feedback is valued at £2.69m.
Download the latest AIM Journal from http://www.hubinvest.com/ AIMPDFNovember2014_62
© 2021 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.